NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Keros Therapeutics, Inc. (KROS) has been on a downward spiral lately with significant selling pressure. After declining 39.2% over the past four weeks, the stock looks well positioned for a trend ...

Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Check the time stamp on this data. Updated AI-Generated Signals for Keros Therapeutics Inc. (KROS) available here: KROS. Type a few symbols and Take a Trial. The signals for these will appear ...

Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So should Keros Therapeutics (NASDAQ:KROS) shareholders be worried about its cash burn?

Keros Therapeutics (NASDAQ:KROS – Free Report) had its price target lowered by Piper Sandler from $40.00 to $15.00 in a research report report published on Friday,Benzinga reports. The firm currently ...

Subscribers also receive market analysis, stock correlation tools, macroeconomic observations, timing tools, and protection from market crashes using Evitar Corte.

Keros Therapeutics (NASDAQ:KROS – Get Free Report) had its target price cut by equities research analysts at Oppenheimer from ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Keros Therapeutics, Inc. (KROS) has been on a downward spiral lately with significant selling pressure. After declining 39.2% over the past four weeks, the stock looks well positioned for a trend ...